SEC Filings

Form 10-Q
PROTAGONIST THERAPEUTICS, INC filed this Form 10-Q on 11/06/2018
Document Outline
Entire Document (4520.6 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - PROTAGONIST THERAPEUTICS, INC.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - PROTAGONIST THERAPEUTICS, INC.
Page 5 - PROTAGONIST THERAPEUTICS, INC.
Page 6 - PROTAGONIST THERAPEUTICS, INC.
Page 7 - PROTAGONIST THERAPEUTICS, INC.
Page 8 - PROTAGONIST THERAPEUTICS, INC.
Page 9 - PROTAGONIST THERAPEUTICS, INC.
Page 10 - PROTAGONIST THERAPEUTICS, INC.
Page 11 - PROTAGONIST THERAPEUTICS, INC.
Page 12 - PROTAGONIST THERAPEUTICS, INC.
Page 13 - PROTAGONIST THERAPEUTICS, INC.
Page 14 - PROTAGONIST THERAPEUTICS, INC.
Page 15 - PROTAGONIST THERAPEUTICS, INC.
Page 16 - PROTAGONIST THERAPEUTICS, INC.
Page 17 - PROTAGONIST THERAPEUTICS, INC.
Page 18 - PROTAGONIST THERAPEUTICS, INC.
Page 19 - PROTAGONIST THERAPEUTICS, INC.
Page 20 - PROTAGONIST THERAPEUTICS, INC.
Page 21 - PROTAGONIST THERAPEUTICS, INC.
Page 22 - PROTAGONIST THERAPEUTICS, INC.
Page 23 - PROTAGONIST THERAPEUTICS, INC.
Page 24 - PROTAGONIST THERAPEUTICS, INC.
Page 25 - PROTAGONIST THERAPEUTICS, INC.
Page 26 - PROTAGONIST THERAPEUTICS, INC.
Page 27 - PROTAGONIST THERAPEUTICS, INC.
Page 28 - ITEM 2.MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 29 - N/A
Page 30 - Janssen License and Collaboration Agreement
Page 31 - Management s Discussion and Analysis of Financial Condition and Results of Operations Critical Accou
Page 32 - N/A
Page 33 - General and Administrative Expenses
Page 34 - Research and Development Expenses
Page 35 - License and Collaboration Revenue
Page 36 - N/A
Page 37 - N/A
Page 38 - Cash Flows from Operating Activities
Page 39 - Contractual Obligations and Other Commitments
Page 40 - Changes in Internal Control over Financial Reporting
Page 41 - We are an early clinical-stage biopharmaceutical company with no approved products and no historical
Page 42 - We will require substantial additional funding, which may not be available to us on acceptable terms
Page 43 - N/A
Page 44 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 45 - Risks Related to Our Business and Industry
Page 46 - N/A
Page 47 - If Janssen does not elect to continue the development of PTG-200 through an Opt-In Election, our bus
Page 48 - N/A
Page 49 - Clinical development is a lengthy and expensive process with an uncertain outcome, and results of ea
Page 50 - Enrollment and retention of patients in clinical trials is an expensive and time-consuming process a
Page 51 - All of our peptide-based product candidates other than PTG-100, PTG-200 and PTG-300 are in research
Page 52 - Our proprietary peptide platform may not result in any products of commercial value.
Page 53 - If there are any safety or efficacy results that cause the benefit-risk profile of PTG-200 to become
Page 54 - We face a variety of manufacturing risks and rely on third parties to manufacture our drug substance
Page 55 - We may fail to obtain orphan drug designations from the FDA for our product candidates, as applicabl
Page 56 - We may not be successful in obtaining or maintaining development and commercialization collaboration
Page 57 - We face significant competition from other biotechnology and pharmaceutical companies, and our opera
Page 58 - We have not yet negotiated our agreement with Janssen specifying all of the terms of our Co-Detailin
Page 59 - We currently have no marketing and sales organization. To the extent any of our peptide-based produc
Page 60 - We have focused our limited resources to pursue particular product candidates and indications, and c
Page 61 - If we fail to comply with state and federal healthcare regulatory laws, we could face substantial pe
Page 62 - N/A
Page 63 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain market
Page 64 - N/A
Page 65 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 66 - We may need to expand the size of our organization, and we may experience difficulties in managing t
Page 67 - Significant disruptions of information technology systems or breaches of data security could adverse
Page 68 - Our employees, independent contractors, principal investigators, consultants and vendors may engage
Page 69 - We currently conduct, and intend to continue to conduct, a substantial portion of the clinical trial
Page 70 - Our headquarters and certain of our data storage facilities are located near known earthquake fault
Page 71 - The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to
Page 72 - Risks Related to Our Intellectual Property
Page 73 - N/A
Page 74 - We may be involved in lawsuits to protect or enforce our intellectual property, which could be expen
Page 75 - The lives of any patents issued as a result of our pending or future patent applications may not be
Page 76 - Third party claims of intellectual property infringement may prevent or delay our drug discovery and
Page 77 - We may not identify relevant third party patents or may incorrectly interpret the relevance, scope o
Page 78 - Because of the expense and uncertainty of litigation, we may not be in a position to enforce our int
Page 79 - Obtaining and maintaining patent protection depends on compliance with various procedural, document
Page 80 - Intellectual property rights do not necessarily address all potential threats to our competitive adv
Page 81 - We may be subject to claims challenging the inventorship or ownership of our issued patents, any pat
Page 82 - We may not be successful in obtaining or maintaining necessary rights to our product candidates thro
Page 83 - Risks Related to Ownership of our Common Stock
Page 84 - N/A
Page 85 - Volatility in our share price could subject us to securities class action litigation.*
Page 86 - We are obligated to develop and maintain proper and effective internal controls over financial repor
Page 87 - We are an emerging growth company and as a result of the reduced disclosure and governance requireme
Page 88 - If we sell shares of our common stock in future financings, stockholders may experience immediate di
Page 89 - Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 90 - If securities or industry analysts do not publish research or publish inaccurate or unfavorable rese
Page 91 - Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future
Page 92 - The recently passed comprehensive tax reform bill could adversely affect our business and financial
Page 93 - Provisions under Delaware law and California law could make an acquisition of our company more diffi
Page 94 - EXHIBIT INDEX
Page 95 - N/A
Page 96 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer